State AL
Clinical Trials in Alabama
Alabama is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Alabama and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 192 actively recruiting studies with Alabama sites out of 192 registered in total. The busiest research areas in Alabama are Multiple Myeloma, Sickle Cell Disease, Obesity. Leading sponsors running trials in the state include University of Alabama at Birmingham, AstraZeneca, Novartis Pharmaceuticals. By stage, Alabama trials break down as Phase 1 (29), Phase 2 (58), Phase 3 (53), Phase 4 (11).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Alabama
Frequently Asked Questions — Clinical Trials in Alabama
How many clinical trials are currently recruiting in Alabama?
ClinicalMetric currently tracks 192 actively recruiting clinical trials with at least one location in Alabama. The total number of registered studies—including active but not currently enrolling trials—is 192. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Alabama?
Alabama hosts clinical trials across a broad range of medical conditions, including Multiple Myeloma, Sickle Cell Disease, Obesity, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Alabama serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Alabama?
To join a clinical trial in Alabama, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Alabama maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Alabama
NCT07495852 Phase 3
Recruiting
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost In...
Condition
Glaucoma
Enrollment
510 pts
Location
United States
Sponsor
Glaukos Corporation
NCT02693535 Phase 2
Recruiting
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That...
Condition
Lymphoma, Non-Hodgkin
Enrollment
4,200 pts
Location
United States, Puerto Rico
Sponsor
American Society of Clinical O
NCT07226349 Phase 1
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Ad...
Condition
Advanced Solid Tumor
Enrollment
105 pts
Location
United States, Australia, China
Sponsor
BeOne Medicines
NCT07361510 Phase 3
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participan...
Condition
Non-Small Cell Lung Cancer (NSCLC)
Enrollment
750 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT06773910 Phase 2
Recruiting
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lu...
Condition
Limited Stage Small Cell Lung Cancer
Enrollment
250 pts
Location
United States
Sponsor
SCRI Development Innovations,
NCT07201558 Phase 1
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE P...
Condition
Rheumatoid Arthritis
Enrollment
48 pts
Location
United States, Australia, Belgium
Sponsor
AstraZeneca
NCT07390955 Phase 1
Recruiting
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS i...
Condition
HIV
Enrollment
83 pts
Location
United States, Peru, Zimbabwe
Sponsor
National Institute of Allergy
NCT06294574 N/A
Recruiting
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker i...
Condition
Breast Neoplasm
Enrollment
150 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT06979362 Phase 2
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Struct...
Condition
Heart Failure
Enrollment
200 pts
Location
United States, Canada, Germany
Sponsor
Novo Nordisk A/S
NCT07333261 Phase 1
Recruiting
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Condition
Multiple Myeloma
Enrollment
25 pts
Location
United States
Sponsor
Susan Bal
NCT05787470 N/A
Recruiting
State of Hormones Impact Nociceptive Expression
Condition
Pain
Enrollment
120 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT06527157 N/A
Recruiting
Investigations of Reproductive Cancers in Women
Condition
Uterine Cancer
Enrollment
4,500 pts
Location
United States
Sponsor
PinkDx, Inc.
NCT06875973 Phase 3
Recruiting
Pelacarsen Roll-over Extension Program
Condition
Atherosclerotic Cardiovascular Disease
Enrollment
599 pts
Location
United States, Puerto Rico
Sponsor
Novartis Pharmaceuticals
NCT06906341 Phase 2
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With G...
Condition
Ovarian Cancer
Enrollment
270 pts
Location
United States, Belgium, France
Sponsor
Corcept Therapeutics
NCT06389877 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With A...
Condition
Alpha 1-Antitrypsin Deficiency
Enrollment
106 pts
Location
United States, Australia, Ireland
Sponsor
Beam Therapeutics Inc.
NCT04144894 N/A
Recruiting
The Biosonographic Index
Condition
Acute Kidney Injury
Enrollment
50 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT06603844 Phase 1, Phase 2
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Condition
Solid Tumor
Enrollment
156 pts
Location
United States, United Kingdom
Sponsor
Corbus Pharmaceuticals Inc.
NCT07160244 Phase 3
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregn...
Condition
Healthy
Enrollment
6,000 pts
Location
United States, Argentina, Brazil
Sponsor
Pfizer
NCT04166409 Phase 3
Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients Wit...
Condition
Low Grade Astrocytoma
Enrollment
170 pts
Location
United States, Canada, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT07165028 Phase 3
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associ...
Condition
Metabolic Dysfunction-Associated Steatotic Liver Disease
Enrollment
4,500 pts
Location
United States, Argentina, Australia
Sponsor
Eli Lilly and Company
NCT05762107 Phase 2
Recruiting
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Condition
Type 1 Diabetes Mellitus With Hypoglycemia
Enrollment
186 pts
Location
United States, Canada
Sponsor
Zucara Therapeutics Inc.
NCT06324201 N/A
Recruiting
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use i...
Condition
Paroxysmal Atrial Fibrillation
Enrollment
250 pts
Location
United States
Sponsor
Heart Rhythm Clinical and Rese
NCT05336201 Phase 2
Recruiting
Cognitive Remediation Intervention to Prepare for Transition of Care
Condition
Sickle Cell Disease
Enrollment
120 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT04176198 Phase 1, Phase 2
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Condition
Myelofibrosis
Enrollment
240 pts
Location
United States, Australia, Belgium
Sponsor
Sumitomo Pharma America, Inc.
NCT07288398 Phase 3
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Condition
Pulmonary Hypertension Associated With HFpEF
Enrollment
540 pts
Location
United States, Argentina, Austria
Sponsor
Tenax Therapeutics, Inc.
Page 1 of 8 — 192 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology